Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Fennec Pharmaceuticals Q2 EPS $(0.11) Misses $(0.04) Estimate, Sales $9.65M Beat $9.52M Estimate

Author: Benzinga Newsdesk | August 14, 2025 05:09am
Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.04) by 205.56 percent. This is a 45 percent increase over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $9.65 million which beat the analyst consensus estimate of $9.52 million by 1.42 percent. This is a 32.91 percent increase over sales of $7.26 million the same period last year.

Posted In: FENC


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist